Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naive advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis.

ABSTRACT:

Background

A previous network meta-analysis (NMA) compared the efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive non-small cell lung cancer (NSCLC). The phase III INSPIRE study of iruplinalkib was published recently. The present study aimed to add the results related to iruplinalkib to the NMA.

Methods

A systematic literature search was performed in PubMed, Embase, Cochrane Library, Google, and Baidu. Randomized controlled trials (RCTs) reporting the independent review committee-assessed progression-free survival (PFS), objective response rate (ORR), or disease control rate (DCR) results of Asian patients with ALK inhibitor-naïve advanced ALK-positive NSCLC were eligible for inclusion in the NMA. Risk of bias was assessed using the Cochran

SUBMITTER: Li X 

PROVIDER: S-EPMC11384493 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature